

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A10/2018 WB

DESPATCHED ON 22ND JANUARY 2019

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B44, B57; Cw6, -: DR4, DR7; DQ7, DQ9

					Summary of Results												
					PBL				T-Cells				B-Cells				
Total tested	8	6	8	7	32	30	31	31	32	30	32	29					
Positive	0	6	0	0	2	17	1	9	10	23	3	15					
Negative	8	0	8	7	30	13	30	22	22	7	29	14					
NT	0	2	0	1	3	5	4	4	5	7	5	8					
% Positive	0.0%	100.0%	0.0%	0.0%	6.3%	56.7%	3.2%	29.0%	31.3%	76.7%	9.4%	51.7%					
% Negative	100.0%	0.0%	100.0%	100.0%	93.8%	43.3%	96.8%	71.0%	68.8%	23.3%	90.6%	48.3%					
Consensus	Negative	Positive	Negative	Negative	Negative	Not Assessed	Negative	Not Assessed	Not Assessed	Positive	Negative	Not Assessed					
HLA Antibody Specificity (Defined By CDC)	B7	A10	DR2	B7 B27 Cw	B7	A10	DR2	B7 B27 Cw	B7	A10	DR2	B7 B27 Cw					
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments	
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4		
9	YES	YES	YES	Negative	NT	Negative	NT	Negative	Negative	Negative	Negative	Negative	NT	Negative	NT	Poor cell viability	
11	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative		
12	YES	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Positive		
20	YES	YES	YES	Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive	Positive	Positive	Negative	Negative		
23		YES	YES					Negative	Positive	Negative	Positive	Negative	Positive	Positive	Positive		
24		YES	YES					Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive		
25		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative		
28		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Low cell count and poor viability	
34		YES	YES					Negative	Positive	Negative	Negative	Positive	Positive	Positive	Positive		
38	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Negative	Negative		
39		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive		
41		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
42	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
45		YES	YES					Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative		
51		YES	YES					Positive	Negative	Negative	NT	Positive	Negative	Negative	NT	Poor cell viability	
54		YES	YES					Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive	B-cell rosmatch would be invalid in a clinical setting due to high background	
58		YES	YES					Negative	Positive	Negative	Positive	Positive	Positive	Negative	Positive		
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Low B-cell viability	
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
116		YES	YES					Negative	Positive	Negative	Negative	Positive	Positive	Negative	Positive		
117	YES			Negative	NT	Negative	Negative										
136		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative		
145		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	NT		
149	YES			Negative	Positive	Negative	Negative										
162		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Positive		
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive		
186		YES	YES					Negative	Negative	Negative	Positive	Negative	Positive	Negative	Positive		
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
206		YES	YES					Negative	NT	NT	Positive	Negative	Negative	Negative	Positive	Replicate issue on T cell with serum 2 and 3 without DTT	
223		YES	YES					Negative	Positive	Positive	Positive	NT	Negative	NT	NT	Low B-cell viability	
227		YES	YES					Negative	NT	Negative	Negative	Negative	NT	Negative	Negative	Technical failure	
268		YES	YES					Negative	Positive	Negative	Negative	Negative	Positive	Negative	Positive		
284		YES	YES					Negative	Positive	Negative	Negative	NT	NT	NT	NT	Low B-cell viability	
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive		
311		YES	YES					Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative		
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Crossmatch with DTT was not contributive (IgG positive control was negative)	
406		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned	
411		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	No results returned	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A10/2018 WB

DESPATCHED ON 22ND JANUARY 2019

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	NT	0	NT	0	0	0	0	0	NT	0	NT	80	80	60
11	1	2	1	1	1	4	1	1	1	4	1	1	90	90	50
12	-	40%	-	-	35%	100%	-	90%	50%	100%	-	60%	95	95	98
20	1	8	1	1					2	2	1	1	90	-	90
23					1	8	1	6	1	8	8	6	-	90	90
24					10%	80%	5%	50%	40%	60%	30%	50%	-	95	95
25					1	2	1	1	4	6	1	2	-	100	99
28					NT	NT	NT	NT	NT	NT	NT	NT	-	99	60
34					1	8	1	1	8	8	4	8	-	99	97
38	1	4	1	1	1	6	1	1	1	6	1	1	85	95	85
39					-	2	-	-	-	8	4	8	-	98	98
41					-	-	-	-	-	50%	-	-	-	95	90
42	<10%	40%	<10%	<10%					<10%	<10%	<10%	<10%	85	-	90
45					1	8	1	6	1	1	1	1	-	99	90
51					6-8	-	-	-	6-8	-	-	-	90	90	90
54					5%	30%	5%	10%	70%	99%	45%	99%	-	95	70
58					5	90	5	60	30	95	10	40	-	95	95
101					1	1	1	1	1	4	1	4	-	-	-
114					1	1	1	1	2	4	1	1	-	-	-
116					1	1-2	1	1	1-4	1-6	1-2	2-4	-	98	95
117	1	NT	1	1									75	-	-
136					1	6	1	2	1	8	1	1	-	98	98
145					-	4-6	-	-	-	6-8	-	-	-	100	100
149	-	-	-	-									86	-	-
162					1	1	1	1	4	6	1	4	-	100	100
181					1	1	1	1	2	8	1	6	-	100	100
186					0	0	0	4	0	4	0	2	-	99	99
204					2	2	2	2	2	4	4	4	-	90	90
206					1	-	-	4	1	1	1	4	-	90	90
223					1	8	4	4	-	-	-	-	-	95	20
227					-	-	-	-	-	-	-	-	-	90	90
268					1	4	1	1	1	6	1	4	-	85	80
284					1	6	1	2	-	-	-	-	-	98	50
297					1	2	1	2	2	4	2	4	-	80	80
311					1	8	1	6	1	6	1	1	-	80	80
315					1	1	1	1	1	1	1	1	90	90	90
351															
406															
411					1	1	1	1	1	1	1	1	-	75	65

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A10/2018 WB

DESPATCHED ON 22ND JANUARY 2019

HLA PHENOTYPE OF BLOOD DONOR: HLA-A3, A29; B44, B57; Cw6, -; DR4, DR7; DQ7, DQ9

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	7	6	7	6	27	25	27	25	28	25	28	26				
Positive	0	3	0	0	1	2	0	1	1	4	0	0				
Negative	7	3	7	6	26	23	27	24	27	21	28	26				
NT	0	1	0	1	5	7	5	7	6	9	6	8				
% Positive	0.0%	50.0%	0.0%	0.0%	3.7%	8.0%	0.0%	4.0%	3.6%	16.0%	0.0%	0.0%				
% Negative	100.0%	50.0%	100.0%	100.0%	96.3%	92.0%	100.0%	96.0%	96.4%	84.0%	100.0%	100.0%				
Consensus	<b>Negative</b>	<b>Not Assessed</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>				
HLA Antibody Specificity (Defined By CDC)	B7	A10	DR2	B7 B27 Cw	B7	A10	DR2	B7 B27 Cw	B7	A10	DR2	B7 B27 Cw				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	NT	Negative	NT	Negative	Negative	Negative	Negative	Negative	NT	Negative	NT	Poor cell viability
11	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	Negative	Negative	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
15		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
20	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
24		YES	YES					Negative	Positive	Negative	NT	Negative	Positive	Negative	Negative	Poor cell viability
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Low cell count and poor viability
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
38	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
39		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	IgG control failed on this plate
41		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
42	YES		YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Poor cell viability
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51		YES	YES					Positive	Negative	Negative	NT	Positive	Negative	Negative	NT	Poor cell viability
54		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	B-cell rosmatch would be invalid in a clinical setting due to high background
58		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
101		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Low B-cell viability
114		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
116		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	YES			Negative	Positive	Negative	Negative									
162		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
181		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
186		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
204		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
206		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
227		YES	YES					Negative	NT	Negative	Negative	Negative	NT	Negative	Negative	Replicate issue on T cell with serum 2 and 3 without DTT Technical failure
268		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
284		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Low B-cell viability
297		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Positive	Negative	Positive	Negative	Negative	Negative	Negative	
315		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Crossmatch with DTT was not contributive (IgG positive control was negative)
351		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned
406		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	No results returned
411		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A10/2018 WB

DESPATCHED ON 22ND JANUARY 2019

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	0	NT	0	NT	0	0	0	0	0	NT	0	NT	80	80	60
11	1	2	1	1	-	NT	-	-	1	NT	1	1	90	90	50
12	-	-	-	-	-	-	-	-	-	-	-	-	95	95	98
15					0	0	0	0	0	0	0	0	-	90	90
20	1	1	1	1					1	1	1	1	90	-	90
24					30%	70%	30%	NT	30%	50%	40%	40%	-	95	95
25					1	1	1	1	1	1	1	1	-	100	99
28					NT	NT	NT	NT	NT	NT	NT	NT	-	99	60
34					1	1	1	1	1	1	1	1	-	99	97
38	1	1	1	1	1	1	1	1	1	1	1	1	85	95	85
39					NT	NT	NT	NT	NT	NT	NT	NT	-	98	98
41					-	-	-	-	-	50%	-	-	-	95	90
42	<10%	20%	<10%	<10%					<10%	<10%	<10%	<10%	85	-	90
45					1	1	1	1	1	1	1	1	-	99	90
51					6-8	-	-	NT	6-8	-	-	NT	90	90	90
54					5%	5%	5%	5%	30%	35%	20%	30%	-	95	70
58					5	5	5	5	5	50	5	5	-	95	95
101					1	1	1	1	1	4	1	1	-	-	-
114					1	1	1	1	1	1	1	1	-	-	-
116					1	1	1	1	1	1	1	1	-	98	95
149	-	-	-	-									86	-	-
162					1	1	1	1	1	1	1	1	-	100	100
181					1	1	1	1	1	1	1	1	-	100	100
186					0	0	0	0	0	0	0	0	-	99	99
204					2	2	2	2	2	2	2	2	-	90	90
206					1	1	1	1	1	1	1	1	-	90	90
227					-	-	-	-	-	-	-	-	-	90	90
268					1	1	1	1	1	1	1	1	-	85	80
284					1	1	1	1	-	-	-	-	-	98	50
297					1	1	1	1	1	1	1	1	-	80	80
311					1	6	1	4	1	1	1	1	-	80	80
315					-	-	-	-	-	-	-	-	90	90	90
351															
406															
411					1	1	1	1	1	1	1	1	-	75	65